You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

MAGNESIUM SULFATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Magnesium Sulfate, and when can generic versions of Magnesium Sulfate launch?

Magnesium Sulfate is a drug marketed by B Braun Medical, Aspiro, Exela Pharma, Fresenius Kabi Usa, Hospira, Baxter Hlthcare Corp, Hq Spclt Pharma, Pharmobedient, Amneal, Gland, Milla Pharms, and Mylan Labs Ltd. and is included in twenty NDAs.

The generic ingredient in MAGNESIUM SULFATE is magnesium sulfate. There are one hundred and forty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the magnesium sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Magnesium Sulfate

A generic version of MAGNESIUM SULFATE was approved as magnesium sulfate by FRESENIUS KABI USA on September 8th, 1986.

  Get Started Free

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for MAGNESIUM SULFATE?
  • What are the global sales for MAGNESIUM SULFATE?
  • What is Average Wholesale Price for MAGNESIUM SULFATE?
Summary for MAGNESIUM SULFATE
US Patents:0
Applicants:12
NDAs:20
Finished Product Suppliers / Packagers: 10
Raw Ingredient (Bulk) Api Vendors: 1
Clinical Trials: 392
Patent Applications: 3,879
What excipients (inactive ingredients) are in MAGNESIUM SULFATE?MAGNESIUM SULFATE excipients list
DailyMed Link:MAGNESIUM SULFATE at DailyMed
Drug patent expirations by year for MAGNESIUM SULFATE

US Patents and Regulatory Information for MAGNESIUM SULFATE

MAGNESIUM SULFATE is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hq Spclt Pharma MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 207350-003 Dec 6, 2017 AP RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Gland MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 213917-001 Jul 10, 2020 AP RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Milla Pharms MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 209642-002 Nov 8, 2021 AP RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Fresenius Kabi Usa MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 206485-004 Mar 15, 2016 AP RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
Gland MAGNESIUM SULFATE IN PLASTIC CONTAINER magnesium sulfate INJECTABLE;INJECTION 213917-002 Jul 10, 2020 AP RX No No ⤷  Get Started Free ⤷  Get Started Free ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Market Dynamics and Financial Trajectory for Magnesium Sulfate in the Pharmaceutical Sector

Last updated: September 8, 2025

Introduction

Magnesium sulfate, a chemical compound with the formula MgSO₄, has long-standing applications in medical, industrial, and agricultural domains. In the pharmaceutical landscape, magnesium sulfate primarily serves as an anticonvulsant, tocolytic agent, and magnesium supplement. Its diverse usage, coupled with evolving clinical practices, impacts market trajectories and investor outlooks. This article explores the current market dynamics, growth drivers, challenges, and future financial prospects for magnesium sulfate within the pharmaceutical industry, offering stakeholders a comprehensive understanding of its market landscape.

Market Overview

The global pharmaceutical magnesium sulfate market was valued at approximately USD 400 million in 2022, with projections estimating a compound annual growth rate (CAGR) of around 4.2% from 2023 to 2030 [1]. Its core markets include North America, Europe, and Asia-Pacific, regions characterized by extensive obstetric care, childbirth management, and hospital infrastructure.

Magnesium sulfate's demand correlates strongly with obstetric practices, especially the management of preeclampsia and eclampsia in pregnant women. Additionally, it is employed in the treatment of hypomagnesemia, certain arrhythmias, and as a muscle relaxant, providing a broad application base that sustains steady demand.

Market Dynamics

Driving Factors

1. Rising Prevalence of Preeclampsia and Eclampsia:
Preeclampsia affects approximately 2-8% of pregnancies globally, leading to increased utilization of magnesium sulfate as the gold-standard treatment for seizure prevention. The World Health Organization (WHO) recommends magnesium sulfate as the first-line therapy, catalyzing consistent medical adoption [2].

2. Expanding Hospital Infrastructure and Maternal Care Programs:
Developing healthcare systems in Asia-Pacific and Africa have prioritized maternal healthcare, elevating demand for magnesium sulfate in obstetric management. Investments in hospital infrastructure and training programs enhance accessibility to magnesium sulfate treatments.

3. Growing Awareness and Clinical Guidelines:
Updated clinical guidelines and evidence-based protocols endorse magnesium sulfate usage, reinforcing its role in obstetric emergencies. The integration of such standards into national healthcare policies boosts market stability.

4. Cost-Effective Nature and Ease of Administration:
Magnesium sulfate’s low manufacturing costs and straightforward administration protocols make it a preferred intervention, particularly in resource-constrained settings, ensuring consistent demand and facilitating broader distribution.

Challenging Factors

1. Competition from Alternative Therapies:
While magnesium sulfate remains the mainstay for eclampsia, alternative treatments such as diazepam have been considered, albeit with lower efficacy. The market’s dependence on clinical adherence rather than active competition limits disruption but signals avenues for innovation.

2. Quality Control and Supply Chain Concerns:
Variability in raw material quality, manufacturing standards, and regulatory compliance pose supply chain risks. Poor-quality products could undermine clinical confidence, impacting market growth.

3. Regulatory and Patent Constraints:
Although magnesium sulfate is a generic compound, regulatory hurdles around manufacturing practices and quality standards influence market entry and expansion strategies, especially across different geographic regions.

4. Limited R&D Investment:
Research into new formulations or alternative compounds has been sparse, constraining innovation-driven market growth. The focus remains largely on established formulations.

Market Segmentation and Regional Analysis

By Application:

  • Obstetrics & Gynecology (preeclampsia, eclampsia management) accounts for approximately 75% of global demand.
  • Critical care and neurology utilize magnesium sulfate for arrhythmias and hypomagnesemia.
  • Agricultural and industrial uses are outside the scope of this pharmaceutical analysis.

By Route of Administration:

  • Parenteral administration (intravenous or intramuscular) dominates, with formulations optimized for hospital settings.
  • Oral magnesium sulfate products serve as dietary supplements in select markets.

Regional Insights:

  • North America: Dominates the market (approx. 40%) due to advanced healthcare infrastructure and high obstetric care standards.
  • Europe: Accounts for around 25%, driven by stringent clinical guidelines and regulatory standards.
  • Asia-Pacific: The fastest-growing segment (CAGR > 5%) driven by expanding healthcare access, rising maternal health awareness, and increasing hospitalizations.
  • Emerging Markets: Africa and Latin America show potential growth owing to improved healthcare programs, albeit constrained by supply chain and affordability issues.

Financial Trajectory and Investment Trends

The steady demand for magnesium sulfate is reflected in consistent revenue flows within pharmaceutical supply chains. Manufacturers predominantly focus on generic production, with large players such as Pfizer, Fresenius, and Hikma Pharmaceuticals spearheading supply. Market entries are constrained by regulatory compliance, but high-volume manufacturing ensures economies of scale.

Pricing Dynamics:
Magnesium sulfate's low unit cost maintains high margins despite burgeoning volume sales. Pricing remains competitive globally, but regional regulation influences pricing strategies.

Investment and R&D Outlook:
Investors exhibit cautious optimism. While current demand sustains revenue, prospects for high-value innovations remain limited. Nonetheless, growth in emerging markets, coupled with government-funded health initiatives, is expected to support sales.

Emerging Trends:

  • Development of alternative formulations with improved bioavailability or stability.
  • Focused investments in supply chain resilience amidst geopolitical uncertainties.
  • Expansion into nutraceuticals, leveraging magnesium's health benefits in non-medical segments.

Regulatory and Compliance Considerations

Magnesium sulfate's production and distribution are governed by pharmacopoeial standards, such as USP, EP, and JP monographs. Regulatory bodies like FDA, EMA, and respective national agencies enforce strict manufacturing practices. Ensuring compliance and achieving quality certifications remains pivotal for market access, especially in high-growth regions.

Future Outlook

Forecasts suggest moderate but sustained growth driven primarily by obstetric uses. Emerging markets represent the most dynamic segment, and innovations in formulation and global health policy adoption could further enhance market stability. However, ongoing regulatory challenges and the necessity for quality assurance remain critical considerations for market participants.

Key Challenges and Opportunities

  • Challenges: Supply chain disruptions, regulatory variances, quality control issues, and limited R&D investment.
  • Opportunities: Expansion into emerging markets, strengthening supply networks, and leveraging analytical advances to improve product quality.

Key Takeaways

  • The magnesium sulfate pharmaceutical market is characterized by stable demand, predominantly driven by obstetric indications like preeclampsia and eclampsia management.
  • Growth prospects are favorable in Asia-Pacific and emerging markets due to healthcare infrastructure expansion and increased maternal health awareness.
  • Regulatory compliance and supply chain integrity are critical for sustaining market share.
  • Limited innovation in formulations presents both a challenge and an opportunity for stakeholders to differentiate offerings.
  • Cost-effectiveness and established clinical protocols underpin market stability, but ongoing policy developments and global health initiatives could catalyze future growth.

FAQs

1. What are the main medical applications of magnesium sulfate?
Magnesium sulfate is primarily used to treat preeclampsia and eclampsia in pregnant women, manage magnesium deficiency, control certain arrhythmias, and relax skeletal muscles during surgeries.

2. How does regional regulation impact magnesium sulfate marketing?
Regulatory standards influence manufacturing practices, quality assessments, and market approval processes. Regions with stringent standards, such as Europe and North America, require rigorous compliance, whereas emerging markets may face supply chain hurdles due to inconsistent enforcement.

3. Are there any notable R&D developments for magnesium sulfate?
Research has primarily focused on optimizing formulations for better stability and bioavailability. No significant R&D innovations have disrupted the market recently, owing to the compound’s established clinical use.

4. How do supply chain issues affect the magnesium sulfate market?
Supply chain disruptions can lead to shortages, affecting hospital procurement and patient care continuity. Raw material quality variability and geopolitical factors further exacerbate these issues.

5. What is the long-term growth outlook for magnesium sulfate in pharmaceuticals?
Stable demand driven by obstetric care suggests moderate growth over the next decade. Market expansion into emerging economies, coupled with potential product innovations, could stimulate higher growth rates.

References

[1] Market Research Future. "Global Magnesium Sulfate Market Analysis." 2022.

[2] World Health Organization. "Guidelines for the Management of Preeclampsia and Eclampsia." 2018.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.